Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Sionna Therapeutics, Inc.NASDAQ: SION
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.6, compared with -$0.37 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.93.
Context
- EPS (Diluted) grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 7 analysts of -$2.6 (-38.1%) for the fiscal year ending Dec 2026, a slowdown from the -34.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.6-30.4% QoQ
- Last fiscal yearDec 2025
- -$1.88-34.3% YoY
- LTMMar 2026
- -$1.93-28.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -60.5% | -58.5% | +2.0 pp |
| 1 year | -34.3% | -38.1% | -3.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.88) USD
- Year-over-year change
- -34.3%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.88) | -34.3% |
| FY2024 | 2024-12-31 | (1.40) | -30.7% |
| FY2023 | 2023-12-31 | (1.07) | -17.4% |
| FY2022 | 2022-12-31 | (0.91) | — |
EPS (Diluted) vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 EPS (Diluted) of -$1.93 is the 6th highest of the 11 companies compared; the peer median is -$2.25.
- Its year-over-year change of -28.1% is the 8th highest of 11, against a peer median of +2.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $0.52 | +161.9% | — | |
| LTM Mar 2026 | $0.07 | +121.3% | — | |
| LTM Mar 2026 | -$0.24 | -4.8% | — | |
| LTM Sep 2026 | -$0.48 | +17.2% | — | |
| LTM Mar 2026 | -$1.84 | -35.3% | — | |
| LTM Mar 2026 | -$1.93 | -28.1% | — | |
| LTM Sep 2026 | -$2.65 | +10.2% | — | |
| LTM Mar 2026 | -$2.75 | -4396.9% | — | |
| LTM Sep 2026 | -$4.31 | -27.5% | — | |
| LTM Jun 2026 | -$4.64 | +39.4% | — | |
| LTM Jun 2026 | -$5.86 | -58.0% | — | |
| Peer median (excluding SION) | -$2.25 | +2.7% | — | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 647K |
| Gross Profit | 0 | 0 | (668K) | (647K) |
| Gross Margin | — | — | — | — |
| Research & Development | 34.61M | 40.63M | 57.29M | 60.26M |
| Selling, General & Admin | 6.77M | 9.71M | 13.27M | 28.72M |
| Operating Expenses | 41.37M | 50.33M | 69.89M | 88.34M |
| Depreciation & Amortization | 122K | 583K | 668K | 647K |
| EBITDA | (40.12M) | (46.68M) | (61.02M) | (74.62M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (41.37M) | (50.33M) | (70.56M) | (88.98M) |
| Operating Margin | — | — | — | — |
| Interest Income | 1.13M | 2.77M | 8.17M | 13.3M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.13M | 3.07M | 8.87M | 13.71M |
| Income Before Tax | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.91) | (1.07) | (1.40) | (1.88) |
| EPS (Diluted) | (0.91) | (1.07) | (1.40) | (1.88) |
| Weighted Avg Shares | 44.12M | 44.12M | 44.12M | 39.96M |
| Weighted Avg Shares (Diluted) | 44.12M | 44.12M | 44.12M | 39.96M |
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.